References
- Mardis ER. Next-generation sequencing platforms. Ann Rev Anal Chem 2013;6:287-303
- 21 Code of Federal Regulations § 809.3 In vitro diagnostic products
- Federal Food, Drug, and Cosmetic Act Section § 201(h); 21 U.S.C. § 321(h)
- Zook JM, Chapman B, Wang J, et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat Biotechnol 2014;32:246-51
- Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet. in Med 2004;6(5):387-91
- American college of obstetricians and gynecologists committee on genetics. ACOG Committee Opinion No. 486: update on carrier screening for cystic fibrosis. Obstet Gynecol 2011;117:1028-31
- Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013;45:1160-7
- 21 Code of Federal Regulations § 809.10 Labeling for in vitro diagnostic products
- 21 Code of Federal Regulations § 862.2265 High throughput genomic sequence analyzer for clinical use
- 21 Code of Federal Regulations § 862.3800 Reagents for molecular diagnostic instrument test systems
- FDA News Release: FDA allows marketing of four “next generation” gene sequencing devices. Available from: www.fda.gov/newsevents/newsroom/pressannouncements/ucm375742.htm
- FDA approved or cleared nucleic based tests. Available from: www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm
- Ultra high throughput sequencing for clinical diagnostic applications - approaches to assess analytical validity, june 23. 2011. Available from: www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm255327.htm
- Evaluation of automatic Class III designation for MiSeqDx platform – decision summary. Available from: www.accessdata.fda.gov/cdrh_docs/reviews/K123989.pdf
- Evaluation of automatic Class III designation for MiSeqDx Universal Kit 1.0 – decision summary. Available from: www.accessdata.fda.gov/cdrh_docs/reviews/K133136.pdf
- Genome reference consortium - human genome assembly data (Assembly GRCh37/hg19, Feb. 2009). Available from: http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/data/
- 510(k) substantial equivalence determination – decision summary (K124006). Available from: www.accessdata.fda.gov/cdrh_docs/reviews/K124006.pdf
- Clinical and Functional Translation of CFTR (CFTR2). Available from: www.cftr2.org [Online] September 2013
- 510(k) Substantial equivalence determination – decision summary (K132750). Available from: www.accessdata.fda.gov/cdrh_docs/reviews/K132750.pdf
- k123989 – order granting the request for de novo classification (lists regulation, intended use, and special controls). Available from: www.accessdata.fda.gov/cdrh_docs/pdf12/K123989.pdf
- Public Workshop – Advancing regulatory science for high throughput sequencing devices for microbial identification and detection of antimicrobial resistance markers. April 1. 2014. Available from: www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm386967.htm
- Medical devices - regulatory controls. Available from: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ucm2005378.htm
- US FDA. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm or Code of Federal Regulations Title 21
- US FDA. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm